// App-Quantinova.ai

OT1-07-02 : A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator’s choice in HER2-low breast cancer (DESTINY-Breast04)

Researchers

Presenter

  • Shanu Modi

Principal Investigators

  • Shoichiro Ohtani

  • Caleb Lee

  • Yibin Wang

  • Kapil Saxena

  • David A. Cameron

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan

  • Daiichi Sankyo, Basking Ridge, NJ

  • University of Edinburgh, Cancer Research UK Edinburgh Centre, Edinburgh, United Kingdom

Locations

  • United States

  • Japan

  • United Kingdom

Companies

  • Daiichi Sankyo Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Interstitial lung disease

  • Cardiotoxicity

  • Breast cancer

  • Pulmonary alveolar proteinosis

  • Solid malignancies

Biomarkers

  • Cyclin-dependent kinase 4

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab emtansine

  • Capecitabine

  • Gemcitabine

  • Trastuzumab

  • Paclitaxel

  • Eribulin

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multiple Arm

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03734029

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved